ValiRx confirms new joint venture agreement, acquisition of IP assets

Date: 2019-05-04   Author: Shikha Sinha  Category: #news

ValiRx confirms new joint venture agreement, acquisition of IP assets

ValiRx has reportedly announced two new agreements, an acquisition deal with FIT Biotech and a joint venture with Alpha Blue Ocean.

Apparently, the company acquired intellectual property and patents previously owned by a Finnish company named FIT Biotech. ValiRx also said it had signed a letter of intent with Alpha Blue Ocean (ABO), a corporate financier, outlining the terms of a diagnostic and therapeutic-based collaboration.

Sources familiar with the matter informed that ValiRx will provide the technological, clinical, and scientific development expertise while ABO will focus on commercial and financing activities. The combined portfolio is ideally positioned to address the scientific and large medication needs for future precision genetic editing.

ValiRx would be adding its GeneICE technology and its VAL101, gene silencing compound, to the strategic joint venture, along with the acquired assets from the administrators of FIT. The agreement is signed to establish a diagnostic and a genetic therapeutic joint venture for the additional development of IP assets of FIT Biotech, with the aim to accumulate and progress a genetic-based technologies portfolio.

According to the chief executive of ValiRx, Dr. Satu Vainikka, at the present the area of genetic editing is a very topical subject as gene editing seeks to transform the way the people combat with a range of diseases.

The intellectual property assets of FIT Biotech seemingly balance well with current gene-based technologies of ValiRx and their blend will support the Group in optimizing its position within this medical market, Dr. Satu said.

For the uninitiated, ValiRx Plc is a life science company which primarily focuses on therapeutic development of clinical stage cancer, potentially taking proprietary and new technology for precision medicines towards collaboration and commercialization. It focuses on the new and fresh treatments of cancers and related biomarkers. Their products and technologies can also be applicable to other fields such as inflammatory diseases and neurology.

Source Credit: https://www.proactiveinvestors.co.uk/companies/news/219534/valirx-makes-acquisition-and-inks-joint-venture-deal-219534.html



About Author


Shikha Sinha linkdin-boxtwitter

Shikha Sinha

Shikha currently manages the content team at AlgosOnline. An electrical & electronics engineer by education, she has prior experience in content & technology writing, content marketing, market research, and business development domains. Her other interests inc...

Read More

Post Recommendents

Chrysanthemum Extract Market Size, Demand, Growth, Trends, Segmentation and Forecasts Research to 2026

Author: Ashwin Naphade

Chrysanthemum Extract market report thoroughly expounds on the contingencies created by Covid-19 pandemic in micro-market across regions, and how this governs the overall growth matrix.

The report on Chrysanthemum Extract market provides a...


Chamaemelum Nobile Extract Market to Witness an Outstanding Growth During 2021- 2026

Author: Ashwin Naphade

Chamaemelum Nobile Extract market aims to decode lucrative investment opportunities in the business sphere and educate readers about the bottlenecks created by Covid-19 pandemic.

The report on Chamaemelum Nobile Extract market provides a c...


Chamomilla Recutita Extract Market Insights and In-Depth Analysis 2021-2026 with Types, Products and Key Players

Author: Ashwin Naphade

Chamomilla Recutita Extract market report provides in-depth information about growth catalysts, profitable prospects, restraints, and Covid-19 impact which will influence the growth rate through 2026.

The report on Chamomilla Recutita Extra...